- Report
- August 2025
Global
From €4318EUR$4,900USD£3,793GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €881EUR$1,000USD£774GBP
€1102EUR$1,250USD£968GBP
- Report
- January 2025
- 175 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- June 2025
- 150 Pages
Global
From €2378EUR$2,699USD£2,089GBP
- Report
- June 2024
- 200 Pages
Global
From €5604EUR$6,360USD£4,923GBP
€7006EUR$7,950USD£6,153GBP
- Report
- May 2024
- 187 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- May 2024
- 134 Pages
Global
From €4868EUR$5,524USD£4,276GBP
€5727EUR$6,499USD£5,030GBP
- Report
- July 2022
- 71 Pages
Global
From €1762EUR$2,000USD£1,548GBP
The Hepatitis D Drug market is a subset of the Infectious Diseases Drugs market, focusing on treatments for the Hepatitis D virus. This virus is a serious infection of the liver, and is often contracted in conjunction with the Hepatitis B virus. Treatment for Hepatitis D is typically a combination of antiviral medications and supportive care. These medications are designed to reduce the amount of virus in the body, and to reduce the risk of complications.
The Hepatitis D Drug market is highly competitive, with a number of companies offering treatments for the virus. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb. These companies offer a range of treatments, including antiviral medications, vaccines, and supportive care. Show Less Read more
